Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd is set to deliver a global webcast presentation updating the progress of their cancer and autoimmune disease treatments, including their TACTI-003 and TACTI-004 Phase III trials in first-line treatments for head and neck cancer and non-small cell lung cancer, respectively. The company cautions that the presentation, which contains forward-looking statements, should be viewed alongside past and future public announcements and regulatory filings to fully understand the context and risks involved. Investors and interested parties should not rely solely on the presentation as a source of information but should also refer to official company sources for comprehensive details.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
